Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: The SMART study

European Journal of Preventive Cardiology

Volumn 17, Issue 4, 2010, Pages 424-430

  Achterberg, Sefanja ^a   Cramer, Maarten J m ^b   Jaap, Kappelle L ^a   Gert Jan de, Borst ^b   Visseren, Frank L j ^b   Yolanda Van Der, Graaf ^b   Algra, Ale ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

cerebrovascular disorders; coronary disease; epidemiology; follow up study; peripheral vascular disease

Indexed keywords

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

AGED; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CORONARY STENOSIS; FEMALE; HEMORRHAGE; HOSPITALS, UNIVERSITY; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; OBESITY; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SMOKING; STROKE; TIME FACTORS;

EID: 77955467462     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e3283361ce6     Document Type: Article

References (22)

1. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis andclinical consequences. Ann Intern Med 2001; 134: 224–238.
2. Vickrey BG, Rector TS, Wickstrom SL, Guzy PM, Sloss EM, Gorelick PB, et al Occurrence of secondary ischemic events among persons withatherosclerotic vascular disease. Stroke 2002; 33: 901–906.
3. Muluk SC, Muluk VS, Kelley ME, Whittle JC, Tierney JA, Webster MW, Makaroun MS. Outcome events in patients with claudication: a 15-year study in2777 patients. J Vasc Surg 2001; 33: 251–257.
4. Ferrieres J, Cambou JP, Gayet JL, Herrmann MA, Leizorovicz A. Prognosis of patients with atherothrombotic disease: aprospective survey in a non-hospital setting. Int J Cardiol 2006; 112: 302–307.
5. Simons PC, Algra A, Van de Laak MF, Grobbee DE, Van der Graaf Y. Second manifestations of ARTerial disease (SMART) study:rationale and design. Eur J Epidemiol 1999; 15: 773–781.
6. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh artery study: prevalence of asymptomatic andsymptomatic peripheral arterial disease in the generalpopulation. Int J Epidemiol 1991; 20: 384–392.
7. Second European Consensus document on chronic critical leg ischemia. Circulation 1991; 84: IV1–IV26.
8. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Van Gijn J. Interobserver agreement for the assessment of handicap in strokepatients. Stroke 1988; 19: 604–607.
9. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al International prevalence, recognition, and treatment ofcardiovascular risk factors in outpatients withatherothrombosis. JAMA 2006; 295: 180–189.
10. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Rother J, et al One-year cardiovascular event rates in outpatients withatherothrombosis. JAMA 2007; 297: 1197–1206.
11. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheralarterial disease. N Engl J Med 1992; 326: 381–386.
12. Norman PE, Eikelboom JW, Hankey GJ. Peripheral arterial disease: prognostic significance andprevention of atherothrombotic complications. Med J Aust 2004; 181: 150–154.
13. Bainton D, Sweetnam P, Baker I, Elwood P. Peripheral vascular disease: consequence for survival andassociation with risk factors in the Speedwell prospective heart diseasestudy. Br Heart J 1994; 72: 128–132.
14. Casais P, Luceros AS, Meschengieser S, Fondevila C, Santarelli MT, Lazzari MA. Bleeding risk factors in chronic oral anticoagulation withacenocoumarol. Am J Hematol 2000; 63: 192–196.
15. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A etal; Bleeding Complications of Oral AnticoagulantTreatment: An Inception-Cohort, Prospective Collaborative Study (ISCOAT).Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423–428.
16. Torn M, Bollen WL, Van der Meer FJ, Van der Wall EE, Rosendaal FR. Risks of oral anticoagulant therapy with increasingage. Arch Intern Med 2005; 165: 1527–1532.
17. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysisof risk factors. Arch Intern Med 1993; 153: 1557–1562.
18. Bongard V, Cambou JP, Lezorovcz A, Ferreres J, Vahanan A, Jullen G, et al Comparison of cardiovascular risk factors and drug use in 14544French patients with a history of myocardial infarction, ischaemic strokeand/or peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 2004; 11: 394–402.
19. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin inpatients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339.
20. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronaryartery disease, and peripheral arterial disease. JAMA 2004; 292: 1867–1874.
21. Rigotti NA, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalisedpatients. Cochrane Database Syst Rev 2007:CD001837.
22. Goessens BM, Visseren FL, Sol BG, de Man-van Ginkel JM, Van der Graaf Y. A randomized, controlled trial for risk factor reduction inpatients with symptomatic vascular disease: the multidisciplinary VascularPrevention by Nurses Study (VENUS). Eur J Cardiovasc Prev Rehabil 2006; 13: 996–1003.